Replies to post #245254 on Biotech Values

[DewDiligence]

Thanks for weighing in. Can any non-cell therapy for rrCLL offer a meaningful CR rate at, say, 5 years? We don’t know yet if Breyanzi can do this, but at least it has a chance.

[DewDiligence]

FDA approves LLY’s Jaypirca—(pirtobrutinib)—for rrMCL:

https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jaypircatm-pirtobrutinib-first-and-only-non

This is an accelerated approval based on a single-arm phase-2 cohort (n=120) in which ORR=50%, CR=13%, and median DoR=8.3 months. Jaypirca is a non-covalent BTK inhibitor.